Ann Dermatol.  2019 Aug;31(4):403-413. 10.5021/ad.2019.31.4.403.

Polydeoxyribonucleotides Improve Diabetic Wound Healing in Mouse Animal Model for Experimental Validation

  • 1Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea.
  • 2Department of Medicine, Graduate School, Chung-Ang University, Seoul, Korea.


Wound healing mechanisms is believed to have effects similar to wound healing disorders in diabetic patients, including abnormal inflammatory cells, angiogenesis disorders, and reduced collagen synthesis. Therefore, reestablishment of structural and promoted angiogenesis could be beneficial to promote wound healing process.
Therefore, we investigated whether the polydeoxyribonucleotide (PDRN) that was self-production in Korea, could be useful as an intradermal injection for promoting wound healing. Also, we validate for wound healing effect of PDRN using healing-impaired (db/db) mice.
In this study, we confirmed the effects of PDRN by creating wound models in in vitro and in vivo model. Using an in vitro wound healing assay, we observed that PDRN stimulated closure of wounded monolayers of human fibroblast cells. PDRN (8.25 mg/ml) or phosphate-buffered saline (0.9% NaCl) was injected once daily into the dermis adjacent to the wound for 12 days after skin injury.
Time course observations revealed that mice treated with PDRN showed accelerated wound closure and epidermal and dermal regeneration, enhanced angiogenesis. The wound area and depth decreased at 3, 6, 9, and 12 days after skin injury. Histological evaluation showed an increase of vascular endothelial growth factor, CD31, and collagen fibers in the PDRN group compared with the control group, indicating that PDRN was effective in the treatment of delayed wound healing caused by diabetes.
This study suggests that our PDRN has a wound healing effect in transgenic animal models with cells and diabetes through angiogenesis.


CD31; Diabetes mouse model; Polyribonucleotide; Vascular endothelial growth factor A; Wound healing

MeSH Terms

Animals, Genetically Modified
In Vitro Techniques
Injections, Intradermal
Models, Animal*
Vascular Endothelial Growth Factor A
Wound Healing*
Wounds and Injuries*
Vascular Endothelial Growth Factor A


  • Fig. 1 Effects of polydeoxyribonucleotide (PDRN) on cytotoxicity and proliferation in human dermal fibroblast neonatal (HDF-n) cells. (A) The cytotoxicity of PDRN was measured using CCK-8 reaction solution in on HDF-n cells. The percentage of viable cells was expressed as a proportion of control cell viability, which was set to 100%. (B) The cell proliferation of HDF-n cells at 48 and 72 hours. The number of HDF-n cells treated with PDRN. (C) The cell migration of HDF-n. We observed these results with optical microscopes (CKX41; OLYMPUS, Tokyo, Japan) at each time point (0, 24, 48, and 72 hours). Significant differences from the control group are *p<0.05, **p<0.01.

  • Fig. 2 Polydeoxyribonucleotide (PDRN) stimulates wound healing at diabetic mouse model. (A) Folliscope images (×15) (LeedM, Seoul, Korea). (B) Digital camera images (D3200; Nikon, Tokyo, Japan). It was confirmed that the area of the wounds was reduced visually with time after skin damage. PBS: phosphate-buffered saline.

  • Fig. 3 Polydeoxyribonucleotide (PDRN) decreases wound area and wound depth in diabetic mice. (A) Color-coded surface topography image captured by a PRIMOSLITE optical 3D skin measuring device, (B) graph showing changes in wound area over time after injury. In +Leprdb/+Leprdb mice, the reduction of the wound area in the PDRN-injected group occurred more rapidly than in the phosphate-buffered saline (PBS)-injected group. In both m+/+Leprdb mice and +Leprdb/+Leprdb mice, the wound area decreased faster than in controls, but this difference was not significant. (C) Graph showing changes in wound depth over time after injury. The PDRN-injected +Leprdb/+Leprdb mice recovered at a rate similar to that of PDRN-injected m+/+Leprdb mice, but the recovery of the wound depth was delayed in the PBS-injected +Leprdb/+Leprdb mice. The wound depth of the PBS-injected group was significantly different from that of the PDRN-injected group on days 6 and 9 (*p<0.05) in +Leprdb/+Leprdb mice.

  • Fig. 4 Polydeoxyribonucleotide (PDRN) promotes wound healing with rapid re-epithelization. Hematoxylin-eosin (H&E) staining was performed on paraffin block sections of the skin tissue 3, 6, 12 days after initial wounding. H&E staining revealed that the wounds were recovered in order of PDRN injected group, phosphate-buffered saline (PBS) injected group in the m+/+Leprdb mice and PDRN injected group, PBS injected group in the +Leprdb/+Leprdb mice in the order of date. In the m+/+Leprdb mice group, the difference between PBS injected group and PDRN injected group was not significant in visual examination, but tissue evaluation showed a clear difference between PBS injected group and PDRN injected group. Scale bars=1 mm.

  • Fig. 5 Polydeoxyribonucleotide (PDRN) promotes skin repair in diabetic mice. (A) Masson's trichrome stain. Red: keratin & muscle fiber, blue: collagen & bone, pink: cytoplasm (×40). (B) van Gieson's stain. Blue: nuclei, bright red: collagen, yellow: cytoplasm, muscle, fibrin, and red blood cells. For the hetero-type m+/+Leprdb mice, those injected with phosphate-buffered saline (PBS) and those with PDRN showed no significant differences histologically. However, for diabetic BKS.Cg-+Leprdb/+Leprdb mice, those injected with PDRN showed faster epithelialization of the epidermis around the wound and faster formation of collagen fiber grows compared with those injected with PBS (×100).

  • Fig. 6 Polydeoxyribonucleotide (PDRN) increases expression of vascular endothelial growth factor (VEGF) and CD31 in the regenerating wounds of diabetic mice. Expression levels of VEGF and CD31 in the tissues of animals sacrificed at day 12 after skin injury were confirmed by immunohistochemical staining. (A) VEGF and (B) CD31. (C) Graph of VEGF intensity. (D) Graph of CD31 intensity. In both m+/+Leprdb mice and +Leprdb/+Leprdb mice, the PDRN treatment group showed significantly higher expression of VEGF and CD31 than the PBS treatment group (analysis by Image-Pro plus 7.0), one-way ANOVA (Shapiro–Wilk p>0.05), independent t-test assay (**p<0.01).


1. Oryan A, Alemzadeh E. Effects of insulin on wound healing: a review of animal and human evidences. Life Sci. 2017; 174:59–67.
2. Galeano M, Bitto A, Altavilla D, Minutoli L, Polito F, Calò M, et al. Polydeoxyribonucleotide stimulates angiogenesis and wound healing in the genetically diabetic mouse. Wound Repair Regen. 2008; 16:208–217.
3. Jeong W, Yang CE, Roh TS, Kim JH, Lee JH, Lee WJ. Scar prevention and enhanced wound healing induced by polydeoxyribonucleotide in a rat incisional wound-healing model. Int J Mol Sci. 2017; 18:E1698.
4. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008; 16:585–601.
5. Ebrahimian TG, Pouzoulet F, Squiban C, Buard V, André M, Cousin B, et al. Cell therapy based on adipose tissue-derived stromal cells promotes physiological and pathological wound healing. Arterioscler Thromb Vasc Biol. 2009; 29:503–510.
6. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen. 1999; 7:335–346.
7. Han G, Ceilley R. Chronic wound healing: a review of current management and treatments. Adv Ther. 2017; 34:599–610.
8. Cianfarani F, Zambruno G, Brogelli L, Sera F, Lacal PM, Pesce M, et al. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. Am J Pathol. 2006; 169:1167–1182.
9. Powell RJ, Goodney P, Mendelsohn FO, Moen EK, Annex BH. HGF-0205 Trial Investigators. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J Vasc Surg. 2010; 52:1525–1530.
10. Altavilla D, Bitto A, Polito F, Marini H, Minutoli L, Di Stefano V, et al. Polydeoxyribonucleotide (PDRN): a safe approach to induce therapeutic angiogenesis in peripheral artery occlusive disease and in diabetic foot ulcers. Cardiovasc Hematol Agents Med Chem. 2009; 7:313–321.
11. Kim SK, Huh CK, Lee JH, Kim KW, Kim MY. H Histologic study of bone-forming capacity on polydeoxyribonucleotide combined with demineralized dentin matrix. Maxillofac Plast Reconstr Surg. 2016; 38:7.
12. Veronesi F, Dallari D, Sabbioni G, Carubbi C, Martini L, Fini M. Polydeoxyribonucleotides (PDRNs) from skin to musculoskeletal tissue regeneration via adenosine A2A receptor involvement. J Cell Physiol. 2017; 232:2299–2307.
13. Bitto A, Galeano M, Squadrito F, Minutoli L, Polito F, Dye JF, et al. Polydeoxyribonucleotide improves angiogenesis and wound healing in experimental thermal injury. Crit Care Med. 2008; 36:1594–1602.
14. Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L, et al. Pharmacological activity and clinical use of PDRN. Front Pharmacol. 2017; 8:224.
15. Wu CH, Chang GY, Chang WC, Hsu CT, Chen RS. Wound healing effects of porcine placental extracts on rats with thermal injury. Br J Dermatol. 2003; 148:236–245.
16. Altavilla D, Squadrito F, Polito F, Irrera N, Calò M, Lo Cascio P, et al. Activation of adenosine A2A receptors restores the altered cell-cycle machinery during impaired wound healing in genetically diabetic mice. Surgery. 2011; 149:253–261.
17. Lee SJ, Lee HM, Ji ST, Lee SR, Mar W, Gho YS. 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose blocks endothelial cell growth and tube formation through inhibition of VEGF binding to VEGF receptor. Cancer Lett. 2004; 208:89–94.
18. Montesinos MC, Desai A, Chen JF, Yee H, Schwarzschild MA, Fink JS, et al. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am J Pathol. 2002; 160:2009–2018.
19. Brem H, Stojadinovic O, Diegelmann RF, Entero H, Lee B, Pastar I, et al. Molecular markers in patients with chronic wounds to guide surgical debridement. Mol Med. 2007; 13:30–39.
20. Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007; 117:1219–1222.
21. Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care. 1999; 22:157–162.
22. Christman AL, Selvin E, Margolis DJ, Lazarus GS, Garza LA. Hemoglobin A1c predicts healing rate in diabetic wounds. J Invest Dermatol. 2011; 131:2121–2127.
23. Emmerson E, Campbell L, Davies FC, Ross NL, Ashcroft GS, Krust A, et al. Insulin-like growth factor-1 promotes wound healing in estrogen-deprived mice: new insights into cutaneous IGF-1R/ERα cross talk. J Invest Dermatol. 2012; 132:2838–2848.
24. Lima MH, Caricilli AM, de Abreu LL, Araújo EP, Pelegrinelli FF, Thirone AC, et al. Topical insulin accelerates wound healing in diabetes by enhancing the AKT and ERK pathways: a double-blind placebo-controlled clinical trial. PLoS One. 2012; 7:e36974.
25. Polito F, Bitto A, Galeano M, Irrera N, Marini H, Calò M, et al. Polydeoxyribonucleotide restores blood flow in an experimental model of ischemic skin flaps. J Vasc Surg. 2012; 55:479–488.
26. Yan Y, Zhu L, Hong L, Deng J, Song Y, Chen X. The impact of ranibizumab on the level of intercellular adhesion molecule type 1 in the vitreous of eyes with proliferative diabetic retinopathy. Acta Ophthalmol. 2016; 94:358–364.
Full Text Links
  • AD
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: